The leaders of nine prominent European pharmaceutical firms, including AstraZeneca, GSK, and Novo Nordisk, have issued a formal call to action to European government officials. In a letter titled 'Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach,' the executives expressed concern that the continent is ceding its competitive edge to the United States and China.

The group argues that the current environment in Europe is hindering the development of new medicines and failing to attract the necessary capital to sustain long-term growth. To address this, the signatories are requesting that European governments formally classify the pharmaceutical sector as 'strategic infrastructure.' This designation would theoretically allow for more robust government support, streamlined regulations, and increased investment security. The executives contend that while the situation is critical, a 'comeback' remains achievable if policy changes are implemented to better support the industry's future.